Beam Therapeutics is trading at $26.11 (+4.15%) as broader risk-on sentiment and easing macroeconomic tensions support a rotation back into growth assets.
- The stock is rising alongside major indices as falling oil prices encourage investors to return to risk assets, despite the XBI biotech ETF remaining down for the session.
- There are no company-specific catalysts or fresh announcements driving the move; the price action appears to be a rebound following sector-wide weakness last week.